{
    "clinical_study": {
        "@rank": "21802", 
        "arm_group": {
            "arm_group_label": "patients treated with haloperidol"
        }, 
        "brief_summary": {
            "textblock": "In this epidemiological point prevalence study, medication profiles of patients with\n      haloperidol treatment will be checked for drug interactions with risk of QT-prolongation.\n      Additional clinical risk factors for developing QT-prolongation and safety measurements will\n      be documented."
        }, 
        "brief_title": "Drug Interactions With Risk of QT-prolongation in a General Hospital", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "QT-prolongation", 
        "detailed_description": {
            "textblock": "Study design: epidemiological point prevalence study\n\n      Target population: Patients with haloperidol treatment\n\n      The following aspects will be investigated:\n\n        -  The medication profiles will be checked for drug interactions with risk of\n           QT-prolongation.\n\n        -  Clinical risk factors for developing QT-prolongation (gender, age, (history of)\n           cardiovascular disease, comorbidity,...) and lab results will be collected.\n\n        -  Safety measurements (e.g. ECG) will be documented."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  treatment with haloperidol (started in the hospital)\n\n        Exclusion Criteria:\n\n          -  age < 18 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients who are treated with haloperidol (every tuesday we will make a selection of the\n        patients who received haloperidol on monday)"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043912", 
            "org_study_id": "EV002"
        }, 
        "intervention": {
            "arm_group_label": "patients treated with haloperidol", 
            "intervention_name": "Haloperidol", 
            "intervention_type": "Drug", 
            "other_name": "Haldol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Haloperidol", 
                "Haloperidol decanoate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "QT-prolongation", 
            "Torsade de Pointes", 
            "Haloperidol", 
            "Drug interactions"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "Universitair Ziekenhuis Leuven"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study", 
        "other_outcome": {
            "measure": "number of patients with an ECG before or after the start of haloperidol", 
            "safety_issue": "Yes", 
            "time_frame": "maximum one year before inclusion / one week after inclusion"
        }, 
        "overall_official": {
            "affiliation": "Katholieke Universiteit Leuven", 
            "last_name": "Eline Vandael, PhD-student", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "QTc-interval (corrected for heart rate)", 
            "safety_issue": "Yes", 
            "time_frame": "maximum one year before inclusion / one week after inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043912"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Katholieke Universiteit Leuven", 
            "investigator_full_name": "Eline Vandael", 
            "investigator_title": "PhD-student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "number of drug interactions (with risk of QT-prolongation)", 
            "safety_issue": "Yes", 
            "time_frame": "one week before/after inclusion"
        }, 
        "source": "Katholieke Universiteit Leuven", 
        "sponsors": {
            "collaborator": {
                "agency": "Agentschap voor Innovatie door Wetenschap en Technologie", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Katholieke Universiteit Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}